MX358411B - Uso de un inhiboidor de aurora quinasa y paclitaxel para el tratamiento de cáncer de pulmón. - Google Patents

Uso de un inhiboidor de aurora quinasa y paclitaxel para el tratamiento de cáncer de pulmón.

Info

Publication number
MX358411B
MX358411B MX2014011324A MX2014011324A MX358411B MX 358411 B MX358411 B MX 358411B MX 2014011324 A MX2014011324 A MX 2014011324A MX 2014011324 A MX2014011324 A MX 2014011324A MX 358411 B MX358411 B MX 358411B
Authority
MX
Mexico
Prior art keywords
methods
treating cancer
kinase inhibitors
aurora kinase
treatment
Prior art date
Application number
MX2014011324A
Other languages
English (en)
Other versions
MX2014011324A (es
Inventor
Chakravarty Arijit
A Ecsedy Jeffrey
W Kleinfield Robert
N Le Kha
Chyi Shyu Wen
Venkatakrishnan Karthik
Original Assignee
Millennium Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Millennium Pharm Inc filed Critical Millennium Pharm Inc
Publication of MX2014011324A publication Critical patent/MX2014011324A/es
Publication of MX358411B publication Critical patent/MX358411B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se divulgan métodos para el tratamiento de varios trastornos proliferativos de células. En particular, los métodos divulgados para el tratamiento de varios trastornos proliferativos de células mediante la administración de un inhibidor selectivo de la cinasa Aurora A en combinación con quimioterapia a base de taxano, tal como paclitaxel o docetaxel.
MX2014011324A 2012-03-20 2013-03-19 Uso de un inhiboidor de aurora quinasa y paclitaxel para el tratamiento de cáncer de pulmón. MX358411B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261613258P 2012-03-20 2012-03-20
PCT/US2013/032962 WO2013142491A1 (en) 2012-03-20 2013-03-19 Methods of treating cancer using aurora kinase inhibitors

Publications (2)

Publication Number Publication Date
MX2014011324A MX2014011324A (es) 2014-12-05
MX358411B true MX358411B (es) 2018-08-20

Family

ID=48048255

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014011324A MX358411B (es) 2012-03-20 2013-03-19 Uso de un inhiboidor de aurora quinasa y paclitaxel para el tratamiento de cáncer de pulmón.

Country Status (25)

Country Link
US (2) US20130303519A1 (es)
EP (1) EP2827855B1 (es)
JP (1) JP6373252B2 (es)
KR (1) KR102128866B1 (es)
CN (1) CN104271129A (es)
AU (1) AU2013235275B2 (es)
CA (1) CA2868024A1 (es)
EA (1) EA036434B1 (es)
ES (1) ES2746946T3 (es)
GE (1) GEP20186900B (es)
HK (1) HK1206253A1 (es)
IL (1) IL234686B (es)
IN (1) IN2014DN08477A (es)
JO (1) JO3630B1 (es)
MA (1) MA37438A1 (es)
MX (1) MX358411B (es)
MY (1) MY175225A (es)
NZ (1) NZ700744A (es)
PH (1) PH12014502109A1 (es)
SG (2) SG11201405621UA (es)
TN (1) TN2014000387A1 (es)
TW (1) TWI649082B (es)
UA (1) UA117455C2 (es)
WO (1) WO2013142491A1 (es)
ZA (1) ZA201407551B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130303519A1 (en) 2012-03-20 2013-11-14 Millennium Pharmaceuticals, Inc. Methods of treating cancer using aurora kinase inhibitors
EP3236948A4 (en) * 2014-12-23 2018-10-03 Millennium Pharmaceuticals, Inc. Combination of raf inhibitors and aurora kinase inhibitors
US20190194750A1 (en) * 2015-07-02 2019-06-27 Millennium Pharmaceuticals, Inc. Biomarkers of response to selective inhibitors of aurora a kinase
CN114681455A (zh) * 2018-08-17 2022-07-01 深圳微芯生物科技股份有限公司 组蛋白去乙酰化酶抑制剂与蛋白激酶抑制剂之组合及其制药用途

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4099012A (en) 1975-08-28 1978-07-04 Ciba-Geigy Corporation 2-pyrazolyl-benzophenones
US4481142A (en) 1979-02-07 1984-11-06 Hoffmann-La Roche Inc. Pyrimido-2-benzazepines
FR2450833A1 (fr) 1979-02-07 1980-10-03 Hoffmann La Roche Derives de benzazepine
US4469633A (en) 1980-05-16 1984-09-04 Hoffmann-La Roche Inc. N-oxides of 5-oxo-1-phenyl-2-benzazepines
EP0273697A3 (en) 1986-12-30 1989-11-29 Merck & Co. Inc. 2-benzazepines with 5- and 6- membered heterocyclic rings
US5166151A (en) 1988-03-25 1992-11-24 Merck & Co., Inc. 2-Benzazepines with 5- and 6-membered heterocyclic rings, compositions and medical methods of use thereof
US5210082A (en) 1991-05-16 1993-05-11 Merck & Co., Inc. 2-benzazepines with 5- and 6-membered heterocyclic rings to treat pain and anxiety disorders
US6096331A (en) 1993-02-22 2000-08-01 Vivorx Pharmaceuticals, Inc. Methods and compositions useful for administration of chemotherapeutic agents
US5747487A (en) 1993-07-29 1998-05-05 American Cyanamid Company Tricyclic benzazepine vasopressin antagonists
GB9523675D0 (en) 1995-11-20 1996-01-24 Celltech Therapeutics Ltd Chemical compounds
CA2247453A1 (en) 1996-03-08 1997-09-12 Joseph James Lewis Azolobenzazepine derivatives as neurologically active agents
US6057329A (en) 1996-12-23 2000-05-02 Celltech Therapeutics Limited Fused polycyclic 2-aminopyrimidine derivatives
GB9713087D0 (en) 1997-06-20 1997-08-27 Celltech Therapeutics Ltd Chemical compounds
AU744636B2 (en) 1997-09-29 2002-02-28 Meiji Seika Pharma Co., Ltd. Tricyclic triazolobenzazepine derivatives, process for producing the same, and antiallergic
US6277844B1 (en) 1998-09-14 2001-08-21 Sydney Spector Compound for selective treatment of malignant cells by inhibiting cell cycle progression, decreasing Bcl2, and increasing apoptosis
US6417207B1 (en) 1999-05-12 2002-07-09 Nitromed, Inc. Nitrosated and nitrosylated potassium channel activators, compositions and methods of use
DE60120193T2 (de) 2000-09-15 2007-03-29 Vertex Pharmaceuticals Inc., Cambridge Pyrazolverbindungen als protein-kinasehemmer
ATE528303T1 (de) 2000-12-21 2011-10-15 Vertex Pharma Pyrazoleverbindungen als proteinkinasehemmer
SI20848A (sl) 2001-03-14 2002-10-31 Lek, Tovarna Farmacevtskih In Kemijskih Izdelkov, D.D. Farmacevtska formulacija, ki vsebuje atorvastatin kalcij
US6686352B2 (en) 2001-05-18 2004-02-03 Hoffmann-La Roche Inc. Substituted imidazo [1,5-a] pyrimido [5,4-d] [1] benzazepine derivatives
DE10135457A1 (de) 2001-07-20 2003-02-06 Adc Automotive Dist Control Optische Sensoranordnung
NZ530741A (en) 2001-08-09 2006-08-31 Actelion Pharmaceuticals Ltd Novel benzo-fused heterocycles as endothelin antagonists
CN1897950A (zh) 2003-10-14 2007-01-17 惠氏公司 稠合芳基和杂芳基衍生物及其使用方法
WO2005076987A2 (en) 2004-02-10 2005-08-25 Santarus, Inc. Combination of proton pump inhibitor, buffering agent, and nonsteroidal anti-inflammatory agent
ATE381566T1 (de) 2004-05-14 2008-01-15 Millennium Pharm Inc Verbindungen und verfahren zur inhibierung der mitotischen progression durch hemmung von aurorakinase
US8153630B2 (en) 2004-11-17 2012-04-10 Miikana Therapeutics, Inc. Kinase inhibitors
EP1836188A1 (en) 2004-12-30 2007-09-26 Astex Therapeutics Limited Pyrazole derivatives as that modulate the activity of cdk, gsk and aurora kinases
CA2634787C (en) 2005-12-23 2014-10-21 Smithkline Beecham Corporation Azaindole inhibitors of aurora kinases
EP1973532A1 (en) 2006-01-16 2008-10-01 Jubilant Organosys Limited Stable pharmaceutical formulation of an acid labile compound and process for preparing the same
WO2008020314A2 (en) 2006-03-14 2008-02-21 Ranbaxy Laboratories Limited Statin stabilizing dosage formulations
DE102006012301A1 (de) 2006-03-15 2007-09-20 Cemag-Anlagenbau-Dessau Gmbh Herstellung von Zementklinker
US7718648B2 (en) 2006-08-09 2010-05-18 Millennium Pharmaceuticals, Inc. Pyridobenzazepine compounds and methods for inhibiting mitotic progression
WO2008054808A2 (en) 2006-10-31 2008-05-08 Achillion Pharmaceuticals, Inc. Elvucitabine pharmaceutical compositions
CL2007003244A1 (es) * 2006-11-16 2008-04-04 Millennium Pharm Inc Compuestos derivados de pirimido[5,4-d][2]benzazepina; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del cancer.
AR065802A1 (es) 2007-03-22 2009-07-01 Schering Corp Formulaciones de comprimidos que contienen sales de 8- [( 1- ( 3,5- bis- (trifluorometil) fenil) -etoxi ) - metil) -8- fenil -1, 7- diaza- spiro [ 4,5] decan -2- ona y comprimidos elaborados a partir de estas
US20090203671A1 (en) 2007-11-27 2009-08-13 Abbott Laboratories Method of treating cancer
WO2009114703A2 (en) * 2008-03-12 2009-09-17 Fox Chase Cancer Center Combination therapy for the treatment of cancer
WO2009158687A1 (en) 2008-06-26 2009-12-30 Anterios, Inc. Dermal delivery
JO3635B1 (ar) 2009-05-18 2020-08-27 Millennium Pharm Inc مركبات صيدلانية صلبة وطرق لانتاجها
JO3434B1 (ar) 2009-07-31 2019-10-20 Millennium Pharm Inc مركبات صيدلانية لمعالجة السرطان وامراض واضطرابات اخري
CA2788774A1 (en) * 2010-02-19 2011-08-25 Millennium Pharmaceuticals, Inc. Crystalline forms of sodium 4-{[9-chloro-7-(2-fluoro-6-methoxyphenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino}-2-methoxybenzoate
US20130303519A1 (en) 2012-03-20 2013-11-14 Millennium Pharmaceuticals, Inc. Methods of treating cancer using aurora kinase inhibitors

Also Published As

Publication number Publication date
MY175225A (en) 2020-06-16
SG11201405621UA (en) 2014-10-30
EA201491727A1 (ru) 2015-01-30
JO3630B1 (ar) 2020-08-27
PH12014502109A1 (en) 2014-12-10
NZ700744A (en) 2016-09-30
EP2827855A1 (en) 2015-01-28
US20160193224A1 (en) 2016-07-07
KR102128866B1 (ko) 2020-07-01
GEP20186900B (en) 2018-10-10
AU2013235275A1 (en) 2014-10-23
JP2015510945A (ja) 2015-04-13
TN2014000387A1 (en) 2015-12-21
MA37438A1 (fr) 2016-05-31
IN2014DN08477A (es) 2015-05-08
TW201343169A (zh) 2013-11-01
WO2013142491A1 (en) 2013-09-26
ES2746946T3 (es) 2020-03-09
EA036434B1 (ru) 2020-11-10
EP2827855B1 (en) 2019-06-26
JP6373252B2 (ja) 2018-08-15
MX2014011324A (es) 2014-12-05
ZA201407551B (en) 2019-01-30
IL234686A0 (en) 2014-11-30
UA117455C2 (uk) 2018-08-10
US10213436B2 (en) 2019-02-26
HK1206253A1 (en) 2016-01-08
SG10201607741RA (en) 2016-11-29
CA2868024A1 (en) 2013-09-26
KR20140144215A (ko) 2014-12-18
US20130303519A1 (en) 2013-11-14
TWI649082B (zh) 2019-02-01
CN104271129A (zh) 2015-01-07
AU2013235275B2 (en) 2017-12-07
IL234686B (en) 2020-01-30

Similar Documents

Publication Publication Date Title
EA201300810A1 (ru) Противораковая терапия с использованием двойных ингибиторов киназ аврора/мек
MX2015008898A (es) Metodos para el tratamiento de cancer pancreatico.
WO2013177187A3 (en) Synergistic tumor treatment with extended-pk il-2 and therapeutic agents
MX2020004986A (es) Composiciones mejoradas para tratar distrofia muscular.
MX2015011753A (es) Metodos para tratar cancer de vegija.
PL2922828T3 (pl) Pochodne 4,6-diaminopirymidynowe jako inhibitory bmi-1 w leczeniu raka
MX2016004678A (es) Composiciones para el tratamiento del cancer.
MX2014012477A (es) Inhibidores pirrolopirazona de tanquirasa.
BR112014024017A8 (pt) Métodos de tratamento de um tipo de câncer, de tratamento do carcinoma, para selecionar uma terapia e para quantificação e inibidor de her3
MX2015010791A (es) Metodos para tratar el cancer y prevenir la resistencia a farmacos.
MX2015013177A (es) Combinacion de tratamientod de cancer usando microarns e inhibidores de egfr-tki.
MX2019010098A (es) Antiandrogenos para el tratamiento del cancer de prostata resistente a la castracion no metastasico.
WO2013134407A3 (en) Procaspase 3 activation by combination therapy
WO2016160621A3 (en) Nk-92 cells in combination therapy with cancer drugs
AU2018253600A1 (en) Dosage forms and therapeutic uses of l-4-chlorokynurenine
MX2017012553A (es) Compuestos espirociclicos.
MX2016015568A (es) Derivados de nucleosidos para el tratamiento del cancer.
PH12014502109A1 (en) Methods of treating cancer using aurora kinase inhibitors
MX2015013021A (es) 5-bromo-indirrubinas.
WO2013106460A3 (en) Compositions and methods for treating malignant astrocytomas
MX359209B (es) Terapia de combinacion de procaspasa para gliobastoma.
WO2016054237A3 (en) Poly (adp-ribose) polymerase 1 inhibitors structurally unrelated to nad
GB2507700A (en) Compositions and methods for treatment of metastatic cancer
MX356102B (es) Compuestos y métodos para tratar leucemia.
MX350868B (es) Medicamentos y metodos para tratar cancer.

Legal Events

Date Code Title Description
FG Grant or registration